Neuroscientific Biopharmaceuticals (ASX:NSB) share price jumps 9% before trading halt

It's been an interesting day on the ASX for the Australian biotech company. Here are the details

| More on:
health worker wearing personal protective equipment and gesturing stop with her hands

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Neuroscientific Biopharmaceuticals Ltd (ASX: NSB) share price jumped higher this morning before becoming subject to a trading halt at lunchtime.

Before the pause in trading, the Australian biotech company's shares were exchanging hands at 31.5 cents apiece, an 8.6% leap from the open. The share price gain came after an update was released to the market prior to the opening bell.

What did Neuroscientific announce today?

Neuroscientific shares jumped on Thursday as the company provided an update on its EmtinB label.

According to Neuroscientific, "EmtinB is currently being developed as a treatment for neurodegenerative dementia and Alzheimer's disease, and degenerative conditions of the optic nerve".

The announcement said EmtinB was shown to be effective in reducing "important biomarkers" associated with severe COVID-19. The study demonstrated Neuroscientific's label was effective in reducing these biomarkers by "more than 50%", versus controls.

As such, this indicates a "strong therapeutic potential" for EmtinB, "in preventing severe immune responses" from COVID-19.

Neuroscientific's hypothesis in examining EmtinB in COVID-19 was to address the "cytokine storm" that occurs with an aggressive inflammatory response in COVID-19 infection.

For example, this "storm" results in a cascade of uncontrolled inflammation in the body, which decreases a person's lung function. A rise in the incidence of these events has been purported with COVID-19, thereby leading Neuroscientific to conduct its trial.

The results obtained suggest EmtinB "is safe to administer in future work", and are an important milestone for the company.

Why are Neuroscientific shares in a trading halt?

Shares paused trading just after midday on Thursday, with the company stating it was working to "finalise an announcement detailing further information in regard to the results from pulmonary studies as announced today".

The halt will remain in place until Monday 23 August, or until the announcement is released to the market.

Neuroscientific share price snapshot

The Neuroscientific Biopharmaceuticals share price has posted a year-to-date return of 26%, extending the previous 12 months' climb of 31%.

These returns have both outpaced the S&P/ASX 200 Index (ASX: XJO)'s gain of around 25% over the last year.

The author Zach Bristow has no positions in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Boys making faces and flexing.
Opinions

3 ASX 300 shares to buy and hold for the long run

I believe these stocks have loads of growth potential.

Read more »

Young girl drinking milk showing off muscles.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a great end to the trading week for ASX investors today.

Read more »

Hands reaching high for a trophy with a sunset in the background.
Record Highs

The ASX 200 Index is on its way to another all-time high today. Here's why

These blue chip stocks are driving the index towards a new record today...

Read more »

Group of friends trading stocks on their phones. symbolising the 3 most traded ASX 200 shares today
Share Market News

3 ASX mining stocks topping the most-traded list in October

Chinese stimulus news and company announcements likely contributed to the higher trading activity.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Share Gainers

3 ASX 200 stocks smashing the benchmark this week

These three ASX 200 stocks are leading the charge this week. Here’s how.

Read more »

Two people tired and resting after sports race.
Broker Notes

Fundie rates 2 ASX 200 stocks in short-term pain but with long-term gain potential

Blackwattle Investment Partners sees these 2 ASX 200 stocks as worthy of a buy and hold strategy.

Read more »

A young woman holding her phone smiles broadly and looks excited, after receiving good news.
Share Gainers

Why A2 Milk, EOS, GQG, and Mineral Resources shares are racing higher today

These shares are ending the week strongly. But why?

Read more »

A male investor wearing a blue shirt looks off to the side with a miffed look on his face as the share price declines.
Share Fallers

Why Megaport, Pilbara Minerals, Vysarn, and WiseTech shares are falling today

These shares are ending the week in the red. But why?

Read more »